Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese journal of integrative medicine ; (12): 31-36, 2019.
Article Dans Anglais | WPRIM | ID: wpr-773972

Résumé

OBJECTIVES@#To evaluate whether garlicin post-conditioning can attenuate myocardial ischemiareperfusion injury in a catheter-based porcine model of acute myocardial infarction (AMI) by affecting adhesion molecules integrin β1/CD29 and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31).@*METHODS@#Twenty-two swine were devided into 3 groups: 6 in a sham-operation group, and 8 each in the model and garlicin groups. AMI porcine model was established in the model and garlicin groups. The distal parts of the left anterior descending coronary artery in the animals of the model and garlicin groups were occluded by dilated balloon for 2 h, followed by reperfusion for 3 h. Garlicin (1.88 mg/kg) was injected over a period of 1 h, beginning just before reperfusion, in the garlicin group. Real-time polymerase chain reaction, immunohistochemistry and Western blot were carried out to detect mRNA and protein expressions of CD29 and CD31 3 h after reperfusion.@*RESULTS@#Hematoxylin-eosin staining showed a better myocardial structure in the garlicin group after reperfusion. Compared to the model group, garlicin inhibited both the mRNA and protein expression of CD29 and CD31 in reperfusion area and no-reflflow area (P<0.05 respectively).@*CONCLUSIONS@#Garlicin post-conditioning induced cardio-protection against myocardial ischemia-reperfusion injury in this catheter-based porcine model of AMI. The cardio-protective effect of garlicin is possibly owing to suppression of production of CD29 and CD31, by inhibition of the mRNA expression of CD29 and CD31.


Sujets)
Animaux , Mâle , Composés allyliques , Pharmacologie , Modèles animaux de maladie humaine , Disulfures , Pharmacologie , Antigènes CD29 , Génétique , Physiologie , Postconditionnement ischémique , Lésion de reperfusion myocardique , Antigènes CD31 , Génétique , ARN messager , Suidae
2.
Chinese Medical Journal ; (24): 2647-2651, 2016.
Article Dans Anglais | WPRIM | ID: wpr-230906

Résumé

<p><b>BACKGROUND</b>The conventional venous access for cardiovascular implantable electronic device (CIED) is the subclavian vein, which is often accompanied by high complication rate. The aim of this study was to assess the efficacy and safety of optimized axillary vein technique.</p><p><b>METHODS</b>A total of 247 patients undergoing CIED implantation were included and assigned to the axillary vein group or the subclavian vein group randomly. Success rate of puncture and complications in the perioperative period and follow-ups were recorded.</p><p><b>RESULTS</b>The overall success rate (95.7% vs. 96.0%) and one-time success rate (68.4% vs. 66.1%) of punctures were similar between the two groups. In the subclavian vein group, pneumothorax occurred in three patients. The subclavian gaps of three patients were too tight to allow operation of the electrode lead. In contrast, there were no puncture-associated complications in the axillary vein group. In the patient follow-ups, two patients in the subclavian vein group had subclavian crush syndrome and both of them received lead replacement. The incidence of complications during the perioperative period and follow-ups of the axillary vein group and the subclavian vein group was 1.6% (2/125) and 8.2% (10/122), respectively (χ2 = 5.813, P = 0.016).</p><p><b>CONCLUSION</b>Optimized axillary vein technique may be superior to the conventional subclavian vein technique for CIED lead placement.</p><p><b>TRIAL REGISTRATION</b>www.clinicaltrials.gov, NCT02358551; https://clinicaltrials.gov/ct2/show/NCT02358551?term=NCT02358551& rank=1.</p>


Sujets)
Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Veine axillaire , Défibrillateurs implantables , Électrodes implantées , Pacemaker , Soins périopératoires , Pneumothorax , Diagnostic , Complications postopératoires , Implantation de prothèse , Veine subclavière
SÉLECTION CITATIONS
Détails de la recherche